R&D News | pharmaphorum

News

After disappointing trial, Editas puts lead CRISPR drug on h...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial.

News

shutterstock_t_cell_immune - Cancer Research UK

Regeneron, CytomX announce bispecific therapeutics for cance...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc.

News

Takeda's Iclusig bests imatinib in first-line leukaemia tria...

Takeda has a chance of breaking into new territory with its blood cancer therapy Iclusig, after the drug performed better than mainstay therapy imatinib in a phase 3 study of adults with ne

News

14/10/2022. London, United Kingdom. Prime Liz Truss appoints Jeremy Hunt as Chancellor. Official portrait of the Chancellor of the Exchequer Jeremy Hunt. Picture by Andrew Parsons / No 10 Downing Street

Industry body slams UK chancellor's R&D tax credits plan for...

A proposal in UK chancellor Jeremy Hunt's autumn statement to overhaul the R&D tax credits system – for small and medium-sized enterprises (SMEs) to reduce what he described as "abuse a

News

Astellas nabs lead in claudin 18.2 after positive stomach ca...

Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or gastroesopha

News